Sign In
Buy ARMP
$6.87
-0.210 (-2.97%)
At Close: Jun 22, 2026
Supports Phase 3 readiness of AP-SA02 Non-dilutive DoD funding totals $28.7M to date LOS ANGELES, June 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Co
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
04:30pm, Wednesday, 13'th May 2026
Entered into secured credit agreement with Innoviva for $25 million maturing in 2029 LOS ANGELES, May 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Comp
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
07:00am, Thursday, 07'th May 2026
Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development Advances AP-SA02
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
07:00am, Monday, 04'th May 2026
Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02 LOS ANGELES, May 4, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Arm
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D.
07:00am, Monday, 27'th Apr 2026
LOS ANGELES, April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of hi
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
04:05pm, Wednesday, 25'th Mar 2026
LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of hi
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
07:00am, Thursday, 19'th Mar 2026
LOS ANGELES, March 19, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of hi
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
07:00am, Monday, 23'rd Feb 2026
Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus QIDP Designation provides for five years of market exclusivity and the potential for fast t
FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study First bacteriophage company to advance a clinical candidate to Phase 3 LOS ANGELES, Jan. 13, 2026 /
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Up 12.8% – Still a Buy?
01:50am, Thursday, 04'th Dec 2025
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was up 12.8% during trading on Wednesday. The stock traded as high as $5.99 and last traded at $5.99. Approximately 75,815 shares tra
LOS ANGELES , Nov. 18, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-pu
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
06:26pm, Wednesday, 12'th Nov 2025
Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.42 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.15 per share a year ago.
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
04:05pm, Wednesday, 12'th Nov 2025
LOS ANGELES , Nov. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-p
LOS ANGELES , Nov. 10, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-pu
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?
08:11am, Thursday, 23'rd Oct 2025
Armata Pharmaceuticals (ARMP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
